Dietary management of inflammatory bowel disease (IBD) is gaining recognition as a crucial component of treatment, with growing evidence supporting the role of diet in modulating disease activity, maintaining remission, and improving quality of life. As we better understand the complex interplay between diet, gut microbiota, and immune responses, it becomes clear that a one-size-fits-all approach to dietary management is no longer sufficient. Instead, personalized nutrition strategies tailored to individual needs and disease phenotypes are emerging as a promising approach.
The current landscape of dietary interventions for IBD is characterized by a wide range of strategies, each with its own rationale and composition. Exclusive enteral nutrition (EEN), a nutritionally complete liquid formula, remains the most established and effective dietary option for inducing remission in Crohn’s disease, particularly in pediatric patients. However, its restrictive nature and limited feasibility for long-term use have led to the development of alternative whole-food-based approaches, such as the Crohn’s disease exclusion diet (CDED) and the Mediterranean diet (MED).
The CDED, a structured three-phase whole-food diet, has shown promise in inducing and maintaining remission in both pediatric and adult patients with Crohn’s disease. By excluding components hypothesized to promote inflammation, such as animal fat, wheat, dairy, gluten, and food additives, and emphasizing the consumption of mandatory foods like chicken breast, eggs, potato, apples, and bananas, the CDED offers a more flexible and sustainable alternative to EEN.
In contrast, the MED, a plant-based diet emphasizing fiber, monounsaturated fats, and antioxidants, has been associated with improved outcomes and quality of life in both Crohn’s disease and ulcerative colitis. A recent study found that adherence to the MED was inversely associated with steroid use and relapse rates in patients with IBD, highlighting the potential benefits of this dietary approach.
While the evidence supporting these dietary interventions is promising, it is essential to acknowledge the limitations and variability in individual responses. The strength of evidence remains limited, and results should be interpreted with caution. Furthermore, the lack of standardized dietary protocols and reliable biomarkers of adherence and response hinders the widespread adoption of these strategies.
Despite these challenges, the future of dietary management in IBD looks promising. Emerging research focuses on defining patient-specific predictors of dietary response, integrating nutritional strategies within precision medicine frameworks, and exploring different implementation models, such as top-down versus step-up dietary approaches. Collaboration between gastroenterologists, dietitians, and researchers is crucial to translating evidence into practice and ensuring that personalized, sustainable nutrition becomes a central component of IBD care.
As we move forward, it is essential to consider the importance of food quality, individual variability, and disease phenotype when evaluating dietary effects in IBD. By doing so, we can tailor interventions to meet the unique needs of each patient, promoting optimal disease management, and improving quality of life. “The key to successful dietary management in IBD is not a single diet, but rather a personalized approach that takes into account the complex interplay between diet, gut microbiota, and immune responses,”*
_This article provides an expert interpretation of published data for educational purposes and should not be considered clinical guidance or a recommendation for patient care._
*_Quoted passages represent the interpretive perspective of the editorial author based on the published data and do not constitute the views of any named individual, organisation, or clinical body. They should not be taken as personal medical advice or used to inform treatment decisions._